CONTINUUS Pharmaceuticals
Stephen Born is a seasoned professional in the field of scientific affairs, currently serving as Senior Director and Head of Scientific Affairs at CONTINUUS Pharmaceuticals since May 2023. Born's extensive experience at CONTINUUS since 2013 includes roles as Director and Manager of Scientific Affairs, where efforts focused on the development of integrated continuous manufacturing processes for APIs, achieving significant cost reductions through data-driven strategies. Prior roles at the Massachusetts Institute of Technology as a Postdoctoral Scientist involved leading process chemistry initiatives at the Novartis-MIT Center for Continuous Manufacturing and contributing to advancements in continuous production processes. Additional experience includes a visiting scientist role at Novartis and postdoctoral research at UC Berkeley. Born holds a Ph.D. in Organic Chemistry from UC San Diego and has completed executive education at MIT Sloan.
CONTINUUS Pharmaceuticals
CONTINUUS’ mission is to produce high-quality drugs that can be delivered to patients more effectively and at a lower cost. CONTINUUS is leveraging a novel continuous manufacturing platform called Integrated Continuous Manufacturing (ICM), initially developed through an $85 M joint research project between Novartis and MIT. With ICM, they will improve affordability and accessibility of pharmaceuticals on a global scale.